Literature DB >> 9951553

Monoassociation with Lactobacillus acidophilus UFV-H2b20 stimulates the immune defense mechanisms of germfree mice.

E Neumann1, M A Oliveira, C M Cabral, L N Moura, J R Nicoli, E C Vieira, D C Cara, G I Podoprigora, L Q Vieira.   

Abstract

Probiotics are formulations containing live microorganisms or microbial stimulants that have some beneficial influence on the maintenance of a balanced intestinal microbiota and on the resistance to infections. The search for probiotics to be used in prevention or treatment of enteric infections, as an alternative to antibiotic therapy, has gained significant impulse in the last few years. Several studies have demonstrated the beneficial effects of lactic acid bacteria in controlling infection by intestinal pathogens and in boosting the host's nonspecific immune response. Here, we studied the use of Lactobacillus acidophilus UFV-H2b20, a lactic acid bacterium isolated from a human newborn from Viçosa, Minas Gerais, Brazil, as a probiotic. A suspension containing 10(8) cells of Lactobacillus acidophilus UFV-H2b20 was inoculated into groups of at least five conventional and germfree Swiss mice to determine its capacity to stimulate the host mononuclear phagocytic activity. We demonstrate that this strain can survive the stressing conditions of the intestinal tract in vivo. Moreover, the monoassociation of germfree mice with this strain for seven days improved the host's macrophage phagocytic capacity, as demonstrated by the clearance of a Gram-negative bacterium inoculated intravenously. Monoassociated mice showed an undetectable number of circulating E. coli, while 0.1% of the original inoculum was still present in germfree animals. Mice treated with viable or heat-killed Lactobacillus acidophilus UFV-H2b20 presented similarly improved clearance capacity when compared with germfree controls. In addition, monoassociated mice had twice the amount of Kupffer cells, which are responsible for the clearance of circulating bacteria, compared to germfree controls. These results suggest that the L. acidophilus strain used here stimulates a nonspecific immune response and is a strong candidate to be used as a probiotic.

Entities:  

Mesh:

Year:  1998        PMID: 9951553     DOI: 10.1590/s0100-879x1998001200009

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  9 in total

Review 1.  The influence of yogurt/Lactobacillus on the innate and acquired immune response.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

2.  Characterization of macrophage-activating lactic acid bacteria isolated from Mukeunji.

Authors:  Jae-Hwan Kim; Jingmei Li; Seon-Kyeong Han; Pei Qin; Jushin Kim; Yeseul Park; Shin-Young Lee; Yeun Hong; Wooki Kim; Hae-Yeong Kim
Journal:  Food Sci Biotechnol       Date:  2016-04-30       Impact factor: 2.391

3.  Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study.

Authors:  M Mego; R Koncekova; E Mikuskova; L Drgona; L Ebringer; L Demitrovicova; I Nemova; J Trupl; J Mardiak; I Koza; V Zajac
Journal:  Support Care Cancer       Date:  2005-09-21       Impact factor: 3.603

4.  Monoassociation with probiotic Lactobacillus delbrueckii UFV-H2b20 stimulates the immune system and protects germfree mice against Listeria monocytogenes infection.

Authors:  Liliane Martins dos Santos; Mônica Morais Santos; Humberto Pereira de Souza Silva; Rosa Maria Esteves Arantes; Jacques Robert Nicoli; Leda Quercia Vieira
Journal:  Med Microbiol Immunol       Date:  2010-09-14       Impact factor: 3.402

Review 5.  Gut microbiome and anticancer immune response: really hot Sh*t!

Authors:  S Viaud; R Daillère; I G Boneca; P Lepage; P Langella; M Chamaillard; M J Pittet; F Ghiringhelli; G Trinchieri; R Goldszmid; L Zitvogel
Journal:  Cell Death Differ       Date:  2014-05-16       Impact factor: 15.828

6.  Effects of the oral administration of viable and heat-killed Streptococcus bovis HC5 cells to pre-sensitized BALB/c mice.

Authors:  Aline D Paiva; Kenner M Fernandes; Roberto S Dias; Alípio S Rocha; Leandro L de Oliveira; Clóvis A Neves; Sérgio O de Paula; Hilário C Mantovani
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

7.  Genetic transformation of novel isolates of chicken Lactobacillus bearing probiotic features for expression of heterologous proteins: a tool to develop live oral vaccines.

Authors:  Rodrigo M Mota; João Luiz S Moreira; Marcelo R Souza; M Fátima Horta; Santuza M R Teixeira; Elisabeth Neumann; Jacques R Nicoli; Alvaro C Nunes
Journal:  BMC Biotechnol       Date:  2006-01-05       Impact factor: 2.563

Review 8.  Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Authors:  Richard Greil; Evelyn Hutterer; Tanja Nicole Hartmann; Lisa Pleyer
Journal:  Cell Commun Signal       Date:  2017-01-19       Impact factor: 5.712

9.  Identification of Lactobacillus UFV H2B20 (probiotic strain) using DNA-DNA hybridization.

Authors:  J T de Magalhães; A P T Uetanabaro; C A de Moraes
Journal:  Braz J Microbiol       Date:  2008-09-01       Impact factor: 2.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.